LRF Clinical Investigator Career Development Award 2027–2030: $375,000 Over Three Years for Early-Career Lymphoma Physician-Scientists

LRF Clinical Investigator Career Development Award 2027–2030: $375,000 Over Three Years for Early-Career Lymphoma Physician-Scientists

Archive status

The Lymphoma Research Foundation (LRF) published a request for proposals titled Clinical Investigator Career Development Award (2027–2030). It set the application deadline at September 3, 2026, at 5:00 PM EST. That deadline has passed. No subsequent CDA application round is announced in the official material available for this check, so this page is a historical reference to the closed 2027–2030 cycle, not an open application notice. It keeps the real deadline for archive and record-keeping purposes; it does not suggest that late applications are accepted.

LRF’s official 2027–2030 CDA RFP is the primary source for the closed round. LRF’s Current Grant Opportunities page is the place to check for a future request for proposals, updated rules, and an active submission link. Researchers planning a future application should rely on the latest LRF RFP and contact the Foundation if the next cycle’s materials do not answer a question. Do not use the archived cycle details below as a substitute for a later RFP.

The 2027 award at a glance

LRF described the CDA as a three-year career-development grant for licensed physician investigators working toward a clinical research career in lymphoma or chronic lymphocytic leukemia (CLL). The published award structure was $375,000 in total, with $120,000 per year in salary support and up to $5,000 per year for eligible incidental expenses. Institutional overhead was not provided. The 2027 call was part of LRF’s early-career grant portfolio; the Foundation’s announcement identifies the program and its application deadline.

The award was designed to help a physician investigator take meaningful responsibility for clinical research rather than simply receive an unrestricted salary supplement. Its career-development component and the proposed study were intended to work together: the candidate would carry out a focused clinical project while gaining the methods, mentorship, and protected time needed to become more independent in lymphoma research.

Purpose and research fit

The CDA supported physician investigators at the advanced-fellow or junior-faculty stage who intended to develop and evaluate lymphoma therapies or diagnostic tools. The project had to be hypothesis-driven and clinical in its primary focus. A proposal could include translational or laboratory elements where appropriate, but an exclusively laboratory-based project was not a fit for this clinical award. At least one clinical research aim needed to be central to the project.

LRF’s stated scope included lymphoma and CLL. The proposal was expected to remain within that disease focus rather than combine lymphoma or CLL with an unrelated cancer or an out-of-scope hematologic malignancy. A persuasive project would make the clinical question, study population, methods, available patient or data resources, and measures of progress understandable to reviewers. It would also explain which parts of the work the applicant would personally lead and how the research would contribute to the applicant’s development as a clinical investigator.

The mechanism placed substantial emphasis on responsibility for clinical study work. Awardees were expected to assume primary responsibility for research design, protocol writing, Institutional Review Board (IRB) submission, study conduct, analysis, and publication of one or more clinical trials during the award period. The application therefore needed to establish both scientific merit and practical capacity: an achievable project, an appropriate institutional setting, sufficient mentorship, and access to the people or information needed to carry out the study.

Eligibility represented in the 2027 cycle

The 2027 cycle was directed to licensed physicians at an academic or nonprofit clinical research institution in the United States or Canada for the award period. LRF specified clinical physicians in ACGME-accredited specialties and gave hematology/oncology, pediatrics, pathology, dermatology, and radiation oncology as examples. Applicants based at the NIH or another U.S. government entity were not eligible under the program terms described for the cycle.

Applicants were to be advanced fellows with at least 24 months of fellowship or postdoctoral training, or junior faculty members. The experience limit was no more than six years after completion of fellowship or postdoctoral training as of March 1, 2027; the cycle materials described flexibility in applying the limit non-sequentially in certain circumstances, such as pregnancy or illness. Candidates with non-traditional career paths could be considered when their experience supported the program’s aims. They were expected to show a strong base in lymphoma biology and treatment and a clear intention to help develop or evaluate new treatments.

The project needed to focus on clinical research in lymphoma or CLL, with a clinical aim as the primary focus. Awardees were expected to devote 35 to 50 percent of their professional time to lymphoma clinical research, free from major patient-care, teaching, or administrative responsibilities that would prevent the protected effort. The application had to make this commitment credible through the work plan and institutional support. The RFP also described a Health Equity Initiative: at least one CDA would support a project focused on underrepresented patient populations and/or an applicant from an underrepresented group. Applicants seeking this funding had to meet an additional U.S. or Canadian citizenship or permanent-residency requirement, alongside the general CDA criteria.

A primary mentor at the applicant’s home institution was required. The mentor was expected to supervise research and career development and support the applicant’s work toward greater independence. The cycle also restricted concurrent career-development awards. Applicants needed to disclose other support and consult the RFP and policy materials about award overlap and which project costs would need to be covered by institutional or other non-career-development funds. Citizenship or permanent residency was not a general requirement for CDA eligibility, although additional conditions could apply to special initiative funding.

Award budget and limits

The published award provided $120,000 in salary support in each of the three award years, plus up to $5,000 annually for incidental costs integral to the Career Development Plan. Eligible examples included research supplies and professional-development expenses such as tuition, registration, and travel for relevant courses or meetings. The incidental amount was a capped category rather than flexible institutional support. No institutional overhead was paid through the CDA.

Applicants preparing the 2027 submission needed to follow the budget fields and definitions in the RFP and Proposal Central application. They also needed to make clear how the proposed salary support related to the effort commitment and how research costs outside the award would be met. Budgeting an expense simply because it supported the institution or project would not make it allowable; the RFP and award terms controlled. The Foundation’s official grants page links to the materials applicants should use for a future round, when one is announced.

How applications were assembled for the closed round

The following summarizes the 2027 application process as an archive. It is not an active checklist: the portal for that round is closed, and requirements can change in a later RFP.

1. Review the RFP and terms. Applicants needed to read the CDA request for proposals and the LRF research-grant policy materials, then review them with the institution’s grants office. Those documents governed eligibility, budget rules, formatting, signatures, and award conditions.
2. Set up Proposal Central. The applicant, institution, signing official, and primary mentor needed working accounts or profiles. The online form could be completed over multiple sessions, but an incomplete application could not be submitted.
3. Develop the clinical research plan. The study needed a clear lymphoma or CLL hypothesis, clinical aims, a feasible design and study population, and a description of the applicant’s own role. The RFP called for a research proposal with aims, background, preliminary work where available, design and methods, feasibility or milestones, relevance to lymphoma, and references.
4. Prepare the Career Development Plan. The applicant needed to describe the training and experience that would support development as a clinical investigator. The research plan and development plan were expected to align: the identified training, methods, and mentorship should address the skills the project and the candidate’s goals required.
5. Confirm mentor and institutional commitments. A primary home-institution mentor needed to document the mentorship and the applicant’s independent contribution. Associate mentors could contribute complementary expertise where permitted by the RFP. The institution also needed to support the promised protected research effort and provide a suitable environment for the clinical work.
6. Collect support letters and required records. The 2027 materials called for a mentor letter and three additional blinded letters of support. Applicants needed to give letter writers enough time to submit through the application system. The submission also required personnel, other support, effort, budget, assurances, and any applicable human-subjects or regulatory information.
7. Build an allowable budget. Applicants needed to use the stated salary support and incidental-cost limits, explain eligible expenses, and leave institutional overhead out of the request. Project costs not covered by the CDA had to be supported through an allowable source.
8. Complete approvals and submit. The applicant, mentor, and authorized institutional official were responsible for completing required electronic signatures and forms. Every letter and attachment had to be in the system before final submission. LRF stated that late applications would not be accepted; the published cutoff for this round was September 3, 2026, at 5:00 PM EST. The RFP set application release on June 1, peer review in September–November, notification in December, and a project start window from March 1 through July 1, 2027.

An applicant preparing for a later round should treat all of those steps as a historical outline only. Before assembling a new submission, confirm whether LRF has issued a new RFP, whether Proposal Central is accepting applications, and whether eligibility, budgets, support letters, required sections, or institutional assurances have changed.

What a competitive application needed to demonstrate

The application needed to connect the candidate’s clinical background, proposed study, and career-development activities in a coherent way. Reviewers should have been able to see why the question mattered to people with lymphoma or CLL, why the selected clinical approach could answer it, and why the applicant was positioned to take responsibility for the work. A project that depended entirely on the mentor’s design or collaborators’ effort would have made the candidate’s development case difficult to evaluate.

Feasibility was equally important. The work plan needed to account for institutional approvals, recruitment or access to records and samples, data quality, analytic expertise, and the time needed to complete each major task. Milestones should be measurable and related to the clinical aims. The applicant’s role in protocol development, study oversight, analysis, and publication should be explicit, while collaborators’ contributions should be clearly defined.

The protected-time commitment had to match the work. A statement that the applicant would devote 35 to 50 percent of effort to research was most credible when paired with an institutional plan to reduce competing clinical, teaching, and administrative duties. Mentor support should describe more than availability: it should explain how the candidate would receive feedback, develop missing skills, and make progress toward independent research responsibility.

The Career Development Plan also needed to be specific to the applicant. Useful components could include training in clinical-trial design, biostatistics, outcomes research, regulatory processes, or another method directly relevant to the proposed study. Planned coursework, seminars, research meetings, and scholarly writing should support identifiable development goals. The strongest plans would connect each activity to a capability the candidate needed for the project and subsequent clinical research career.

Common issues to check against a future RFP

• Confusing this clinical investigator award with a laboratory-focused fellowship or proposing a project whose primary aim is not clinical research.
• Assuming that general oncology eligibility is enough without confirming the LRF disease scope and the applicant’s clinical specialty.
• Overlooking the advanced-fellow training requirement, the experience window, or the protected-effort commitment.
• Naming a mentor without demonstrating a home-institution relationship and a real plan for supervision and career development.
• Leaving the applicant’s independent role unclear when mentors and collaborators contribute to project design or execution.
• Treating incidental funds as general project support or including institutional overhead despite the published restriction.
• Starting letters and institutional approvals too late for a complete online submission.
• Reusing an older budget, form, eligibility rule, or application instruction without checking the next cycle’s official documents.

Questions about the archived 2027 cycle

Can someone apply to the 2027 round now? No. The published deadline was September 3, 2026, and the cycle is closed.

Has LRF announced the next CDA deadline? No later round is announced in the official material linked on this page. Check LRF’s grants page for any new call; do not infer a future deadline from the previous cycle.

What was the 2027 award amount? The published structure was $375,000 over three years, consisting of $120,000 in annual salary support and up to $5,000 per year in eligible incidental funds. Institutional overhead was not allowed.

Who was the award intended for? Licensed clinical physicians at eligible academic or nonprofit institutions in the United States or Canada, generally at advanced-fellow or junior-faculty level, pursuing clinical research in lymphoma or CLL and meeting the cycle’s training and experience rules.

Could the project be laboratory-only? No. The CDA emphasized clinical research. Related translational work could be included, but the clinical aim needed to remain primary.

Where should applicants look for a future round? Start with the Lymphoma Research Foundation’s official grants page. Use the next cycle’s own RFP and policy documents for every current deadline, eligibility condition, application step, and budget rule.

Official source

LRF’s 2027–2030 CDA RFP gives the cycle’s award terms, eligibility, deadlines, and submission instructions. The Foundation’s Current Grant Opportunities page is the program hub for any later announcement. No later deadline is supplied here.